Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Bevacizumab in Advanced Renal Cancer
NCT00126503Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2005
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of BAY 43-9006 (Sorafenib) in Combination With Bevacizumab at 28 days, Maximum Tolerated Dose of Bevacizumab in Combination With BAY 43-9006 (Sorafenib) at 28 days and 1 more. Started May 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00126503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126503.